Malignancy in Children with Trisomy 21

Rabin, Karen R.; Whitlock, James A.

doi:10.1634/theoncologist.2008-0217

Cited by 78 publications

(63 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…treatment than children without DS [2][3][4][5][6]. Remarkably, children with DS AML have a better prognosis than children with non-DS AML.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Acute Myeloid Leukemia Mimicking as Acute Megakaryoblastic Leukemia

Dongre¹,

Taori²

2016

Journal of Hematology and Blood Disorders

View full text Add to dashboard Cite

Down syndrome or constitutional trisomy 21 was linked to leukemia for the first time in a case report published in 1930 since then, down syndrome has been recognized as one of the most important leukemia -predisposing syndromes and patients with down syndrome and leukemia have unique clinical features and significant differences in treatment response toxicity profiles compared to patients without down syndrome. There is approximately 150-fold increase in acute myeloid leukemia in Down Syndrome (DS) children less than 5 years of age; 70% of the cases of AML in Down Syndrome children, less than 4 years of age, are acute megakaryocytic leukemia, in contrast to the 3-6% incidence of this form of leukemia in non-DS chidren [3]. In the WHO classification of tumors of hematopoietic and lymphoid tissues 2008, myeloid proliferations related to down syndrome has been incorporated as a distinct entity. We report a case that morphologically appeared to be megakaryocytic leukemia which on flow cytometry confirmed as AML -NOS. We report a case of rare association of AML-NOS, with down syndrome with sickle cell trait disease.

show abstract

“…treatment than children without DS [2][3][4][5][6]. Remarkably, children with DS AML have a better prognosis than children with non-DS AML.…”

Section: Resultsmentioning

confidence: 99%

“…In addition, children with Down Syndrome are also at increased risk for acute megakaryoblastic leukemia (AMKL) and acute lymphoblastic leukemia (ALL) in the first 4 years of life [2]. When treated with chemotherapy, children with DS also experience more side effects (such as infections and mucositis) from Volume 2 | Issue 2…”

Section: Discussionmentioning

confidence: 99%

Acute Myeloid Leukemia Mimicking as Acute Megakaryoblastic Leukemia

Dongre¹,

Taori²

2016

Journal of Hematology and Blood Disorders

View full text Add to dashboard Cite

show abstract

“…İkincil AML vakaları daha ileri yaşta görülür, tedaviye yanıtı ve prognozu kötüdür 1 . Down Sendromu (DS) myeloid lösemi riskini arttıran (10-20 kat) en önemli kalıtsal hastalık olarak görülmektedir 3 . DS ayrıca bir diğer myeloid hastalık olan geçici myeloproliferatif hastalık ile ilişkilidir.…”

Section: Epidemiyolojiunclassified

“…Tanı anındaki beyaz küre yüksekliği önemli prognostik göstergedir. Yapılan çalışmalarda beyaz küre değerinin <100.000/mm 3 , 100.000-200.000/mm 3 ve ≥400.000/mm 3 olan hastalarda indüksiyon tedavisi esnasından ölüm oranının sırasıyla %1.3, 3.4 ve 10.5 olduğu saptanmıştır 10 . Yeni tanı AML hastalarında SSS tutulumunun olması, prognoz açısından önemli etkide bulunmamaktadır 17 .…”

Section: Prognostik Faktörlerunclassified

Çocukluk Çağında Akut Myeloid Lösemi

Yöntem¹,

Bayram²

2018

Arşiv Kaynak Tarama Dergisi

View full text Add to dashboard Cite

Acute leukemia is basically divided into acute lymphoblastic leukemia and acute myeloid leukemia (AML). About 15-20% of childhood leukemia is caused by AML. AML is classified according to morphological, cytochemical and immunophenotypic characteristics. AML patients may present with various clinical signs and symptoms due to leukemic cell infiltration. Age, gender, race, structural features of the patient and cytogenetic abnormalities are important factors affecting prognosis in AML. The goal in the treatment of AML is to provide complete remission with the least toxicity given to the patient and to maintain this remission. In this study, etiology, classification, clinical features, prognosis and treatment strategies of childhood AML were investigated.

show abstract

“…Patients with Down syndrome (DS) have a higher risk (10-to 20-fold) of developing leukemia [1,2]. In the WHO classification of tumours of haematopoietic and lymphoid tissues 2008, myeloid proliferations related to DS has been incorporated as a distinct entity [3].…”

Section: Introductionmentioning

confidence: 99%

Down Syndrome with Different Hematological Manifestations: A Short Series of 3 Cases with Review of Literature

Manivannan

Prasaad

Kar

et al. 2012

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Children with Down syndrome (DS) present with a spectrum of hematolymphoid malignancies ranging from transient myeloproliferative disorder (TMD) which regress spontaneously to frank acute leukemia of both myeloid and lymphoid lineage. Here we present a series of three cases with different manifestation in DS. Three cases of DS presented with TMD, acute myeloid leukemia (AML-M2) and acute megakaryoblastic leukemia (AMKL), respectively. This case series displays the spectrum of hematological manifestations in children with DS. Although TMD and AMKL are strongly associated with DS, other AML subtypes can also be seen in such patients.

show abstract

Malignancy in Children with Trisomy 21

Cited by 78 publications

References 89 publications

Acute Myeloid Leukemia Mimicking as Acute Megakaryoblastic Leukemia

Acute Myeloid Leukemia Mimicking as Acute Megakaryoblastic Leukemia

Çocukluk Çağında Akut Myeloid Lösemi

Down Syndrome with Different Hematological Manifestations: A Short Series of 3 Cases with Review of Literature

Contact Info

Product

Resources

About